Motif Bio Share Chat (MTFB)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Motif Bio Plc	LSE:MTFB	London	Ordinary Share	GB00BVVT4H71	ORD 1P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+0.00p	+0.00%	2.75p	2.51p	2.99p	-	-	-	0	01:00:00

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	0.0	-11.0	-3.9	-	9

Motif Bio Share Discussion Threads

Showing 4251 to 4273 of 4275 messages

Chat Pages: 171 170 169 168 167 166 165 164 163 162 161 160 Older

Date	Subject	Author	Discuss
22/8/2019 16:31	Dropping 5% on the NASDAQ before UK close does not bode well IMO	buywell3	Read Full Thread Reply
22/8/2019 16:26	Sudden change to a narrower 2.52p v 2.53p....must have been in auction, earlier. f	fillipe	Read Full Thread Reply
22/8/2019 16:17	Must be something going on here - the best bid/ask on show is 2.51p v 3.24p (!). Totals for the bid/ask are 496k v 398k, so there is a hunger there, f	fillipe	Read Full Thread Reply
22/8/2019 10:49	Buywell3 Lost so much money on this there is no point in selling now anyway--very small downside, infinite if unlikely upside. I am sure I am not alone.	pianoduo	Read Full Thread Reply
22/8/2019 09:07	It's been slow going although we do appear to be lifting off the bottom and towards 3p. f	fillipe	Read Full Thread Reply
16/8/2019 16:03	Look at the USA market bullet it's down circa 5% Those guys know more than here IMHO no way is the FDA going to green light this If it does buywell will stop posting PROMISE	buywell3	Read Full Thread Reply
15/8/2019 13:45	A decent rise today....for whatever reason, I know not. f	fillipe	Read Full Thread Reply
12/8/2019 10:44	Pretty poor L2 totals at the bid/ ask - 385k v 1141k. Bests on show are 2.3 p v 2.41p. All fwiw. f	fillipe	Read Full Thread Reply
12/8/2019 09:15	19th Sept, worrying thing is they're monies will run out by then.	zen12	Read Full Thread Reply
11/8/2019 15:49	Is the date of the FDA meeting known yet anyone	best1467	Read Full Thread Reply
26/7/2019 15:33	All indications are it was only the liver toxicity concerns raised by FDA in the CRL. As small crow says the trial may reinforce the FDA concerns or alleviate them. However,I believe a lot of this is about quantifying the risk of Drug Induced Liver Injury(DILI) and the lack of specific biomarkers may mean that the required trial is about generating a sufficient robust body of data. The fact no patients suffered from Hys law or specific concerns over Bilurubin levels is evidential of that outcome.	ivyspivey	Read Full Thread Reply
26/7/2019 15:09	Now 3% lower in the USA More clued up there IMO	buywell2	Read Full Thread Reply
26/7/2019 14:19	That's the risk!	small crow	Read Full Thread Reply
26/7/2019 13:00	cheers small crow. What concerns me is that the results/data might confirm the FDA's concerns, rather than be simply a clinical trial prior to gaining approval.	nick rubens	Read Full Thread Reply
26/7/2019 11:14	The purpose, presumably, is to focus on measuring more reliably any liver toxicity. Not possible to say more as we don't really know exactly what he FDA's objections were.	small crow	Read Full Thread Reply
26/7/2019 09:37	From todays RNS "which indicated that an additional clinical trial will be required prior to granting marketing approval for iclaprim." What's the point/purpose of this clinical trial? Shouldn't it read 'clinical trial required prior to considering approval?'	nick rubens	Read Full Thread Reply
23/7/2019 14:04	Buying now	ultra capital	Read Full Thread Reply
19/7/2019 08:41	The way I see this latest RNS is that the only way MTFB can stay listed on NASDAQ is to do a share consolidation so as to get the US listed share price up to around $3 Will the company do that ? Might be better to just let the NASDAQ listing go	buywell2	Read Full Thread Reply
18/7/2019 08:44	Extract from a SUMMIT RNS issued today. Ignoring the numbers, which are both worrying and mind boggling, it makes we think how difficult it must be to balance potential risk of an antibiotic against "known" benefit. "Infections caused by the bacteria Neisseria gonorrhoeae are a growing global healthcare problem, with an estimated 78 million new cases globally per year. Infection rates continue to rise sharply as highlighted by the Centers for Disease Control and Prevention (‘CDC’), which reported a 19% increase in US gonorrhoea cases in 2017, and Public Health England, which reported a 26% increase in the UK in 2018. Of great concern is the increase in resistance towards the current standard of care treatment for gonorrhoea, a combination of the broad-spectrum antibiotics, azithromycin and ceftriaxone. N. gonorrhoeae resistance rates to azithromycin are 4.4% and rising, and there is an emergence of resistance to ceftriaxone in these same strains, which are referred to as cases of ‘super gonorrhoea.’"	hashertu	Read Full Thread Reply
17/7/2019 09:01	Read AP's post yesterday sums this up nicely, the ones in now are being played with the orchestrated rise yesterday.	zen12	Read Full Thread Reply
16/7/2019 15:50	I have read it	amrishbhim	Read Full Thread Reply
16/7/2019 14:49	You must be living in cloud kookoo land lol It's based on the rns..read yesterday's rns!	zen12	Read Full Thread Reply
16/7/2019 14:35	People please stop writing comments that are based on nothing, the FDA approval will arrive before close of business of month July, they are no funding raising today or next month, speak directly to there broker house, not even considered	amrishbhim	Read Full Thread Reply

Chat Pages: 171 170 169 168 167 166 165 164 163 162 161 160 Older

Your Recent History

LSE

MTFB

Motif Bio

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.